cytokine

PreclinicalBiologic

PPeking University Cancer Hospital & Institute

cytokine is one of 7 biologic programs targeting Pleural effusion. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pleural EffusionActive, not recruiting

Pleural EffusionPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Pleural Effusion

#DrugCompanyPhaseTrials

Sclerosol

SSciarra

Approved

3 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Interleukin-2 (IL2)

Astellas

Phase 1

1 4

JMKX000197

JJemincare

Phase 1

2 5

cytokine

PPeking University Cancer Hospital & Institute

Preclinical

1 6

Recombinant Human Interleukin-2

SSecond Xiangya Hospital of Central South University

Preclinical

1 7

Intrapleural Medications

SSwedish Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pleural effusion1 trial

Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion

Completed·PPeking University Cancer Hospital & Institute··NCT01256801·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for cytokine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cytokine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cytokine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University Cancer Hospital & Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: PPeking University Cancer Hospital & Institute

cytokine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pleural effusion1 trial

References

Drug Info

Quick Facts

Related News